Uploaded December 2024 | Updated September 2026, 1 week ago
At the 2024 RNDS, Dr. Michael Yeaman of UCLA shared an overview of the advances in immunotherapy and tolerization, focusing on the progress made in the field of neuromyelitis optica spectrum disorder (NMOSD) over the past 15 years. Key points included the significant milestones in NMOSD research, the revolution in clinical care, and the emerging technologies aimed at restoring immune tolerance [00:02:03]. Dr. Yeaman discussed the unmet needs in the field, such as the risks associated with current therapies and the need for safer treatments [00:08:12]. The presentation concluded with insights into the exciting future of antigen-specific tolerance as a cure for autoimmune diseases [00:29:39]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Meeting Context
00:17 Overview of Advances in Immunotherapy & Tolerization
00:48 Disclosures and Contributions
01:07 Key Points in NMOSD Research
02:03 NMOSD Revolution and Progress
04:40 Scientific Summary of NMOSD
08:12 Unmet Needs in NMOSD Treatment
11:24 Crash Course in Immune Tolerance
18:18 Restoring Immune Tolerance
20:26 Emerging Technologies in Tolerization
25:19 Recent Advances and Clinical Trials
29:39 Conclusion and Future Outlook
31:23 Closing Remarks and Resources
At the 2024 RNDS, Dr. Michael Yeaman of UCLA shared an overview of the advances in immunotherapy and tolerization, focusing on the progress made in the field of neuromyelitis optica spectrum disorder (NMOSD) over the past 15 years. Key points included the significant milestones in NMOSD research, the revolution in clinical care, and the emerging technologies aimed at restoring immune tolerance [00:02:03]. Dr. Yeaman discussed the unmet needs in the field, such as the risks associated with current therapies and the need for safer treatments [00:08:12]. The presentation concluded with insights into the exciting future of antigen-specific tolerance as a cure for autoimmune diseases [00:29:39]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Meeting Context
00:17 Overview of Advances in Immunotherapy & Tolerization
00:48 Disclosures and Contributions
01:07 Key Points in NMOSD Research
02:03 NMOSD Revolution and Progress
04:40 Scientific Summary of NMOSD
08:12 Unmet Needs in NMOSD Treatment
11:24 Crash Course in Immune Tolerance
18:18 Restoring Immune Tolerance
20:26 Emerging Technologies in Tolerization
25:19 Recent Advances and Clinical Trials
29:39 Conclusion and Future Outlook
31:23 Closing Remarks and Resources
